KALA BIO (KALA) to Release Earnings on Tuesday

Key Points

• KALA BIO is set to release its Q2 2025 earnings on August 5th, with analysts estimating earnings of ($1.82) per share for the quarter.
• The company's stock has experienced significant volatility, opening at $7.93 and previously reaching a twelve-month high of $11.20.
• Several analysts have recently revised their ratings on KALA BIO, with Wall Street Zen upgrading to a "hold" and Oppenheimer maintaining an "outperform" rating with a target price of $15.00.

KALA BIO (NASDAQ:KALA - Get Free Report) is projected to release its Q2 2025 earnings data before the market opens on Tuesday, August 5th. Analysts expect KALA BIO to post earnings of ($1.82) per share for the quarter.

KALA BIO Trading Down 15.0%

KALA traded down $1.26 during trading on Wednesday, hitting $7.14. 325,686 shares of the company's stock were exchanged, compared to its average volume of 196,041. The stock has a 50 day moving average price of $5.04 and a 200 day moving average price of $5.66. The firm has a market cap of $46.05 million, a P/E ratio of -0.87 and a beta of -1.88. KALA BIO has a 1 year low of $2.92 and a 1 year high of $11.20. The company has a current ratio of 1.99, a quick ratio of 1.99 and a debt-to-equity ratio of 3.19.

Insider Buying and Selling at KALA BIO

In other news, Director Mark T. Iwicki sold 13,227 shares of KALA BIO stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $4.01, for a total value of $53,040.27. Following the transaction, the director directly owned 258,433 shares of the company's stock, valued at $1,036,316.33. This trade represents a 4.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders have sold 41,335 shares of company stock valued at $162,876 over the last quarter. Company insiders own 8.32% of the company's stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in KALA BIO stock. Woodline Partners LP acquired a new stake in shares of KALA BIO, Inc. (NASDAQ:KALA - Free Report) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 258,766 shares of the company's stock, valued at approximately $1,483,000. Woodline Partners LP owned approximately 4.01% of KALA BIO as of its most recent filing with the Securities & Exchange Commission. 24.61% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms recently weighed in on KALA. LADENBURG THALM/SH SH assumed coverage on shares of KALA BIO in a report on Friday, July 11th. They set a "buy" rating and a $12.00 price target for the company. Oppenheimer restated an "outperform" rating and issued a $15.00 price target on shares of KALA BIO in a research report on Monday, June 2nd. HC Wainwright dropped their price objective on shares of KALA BIO from $15.00 to $12.00 and set a "buy" rating on the stock in a report on Friday, May 23rd. Finally, Wall Street Zen upgraded shares of KALA BIO from a "sell" rating to a "hold" rating in a research report on Monday.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.